Once seen as the next big thing in cancer, cytokine-based therapies lost their shine after numerous trial flops, but Synthekine is among a number of companies that believe they can succeed with a next-generation technology.
IL-2 plays a key role in stimulating the body’s immune defense, but taming the cytokine’s short-lived but potent effects into a therapy has proven tricky